FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

SILVER SPRING, Md., Nov. 9, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on‑demand enzyme replacement therapy (ERT) in adult and pediatric…